Holzer Holzer & Fistel, LLC Announces Investigation into Ventrus Biosciences, Inc.

  Holzer Holzer & Fistel, LLC Announces Investigation into Ventrus
  Biosciences, Inc.

Business Wire

ATLANTA -- February 12, 2013

Holzer Holzer & Fistel, LLC is investigating whether Ventrus Biosciences, Inc.
(“Ventrus” or the “Company”) (NASDAQ: VTUS) and/or certain of its officers
complied with the federal securities laws when making statements to investors
between December 17, 2010 and June 22, 2012. Specifically, the investigation
focuses on a series of statements made during that time regarding the
effectiveness of Ventrus’s experimental drug iferanserin, or VEN 309. On June
25, 2012, Ventrus announced that its Phase 3 trial of VEN 309 “failed to
demonstrate an improvement in therapy” and that it had “no immediate plans to
continue development of VEN 309.” The Company’s stock price fell dramatically
on the news.

If you purchased Ventrus common stock between December 17, 2010 and June 22,
2012 and have questions concerning your legal rights, you are encouraged to
contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel Jr.,
Esq. or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or
mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its
practice to vigorous representation of shareholders and investors in
litigation nationwide, including shareholder class action and derivative
litigation. More information about the firm is available through its website,
www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC
has paid for the dissemination of this promotional communication, and Michael
I. Fistel, Jr. is the attorney responsible for its content.

Contact:

Holzer Holzer & Fistel, LLC
Michael I. Fistel, Jr., Esq., 888-508-6832 (toll-free)
mfistel@holzerlaw.com
or
Marshall P. Dees, Esq., 888-508-6832 (toll-free)
mdees@holzerlaw.com
 
Press spacebar to pause and continue. Press esc to stop.